user

U.S. FDA Acknowledges Receipt of Intellipharmaceutics’ Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review

TORONTO, ON / ACCESSWIRE / March 29, 2019 / Intellipharmaceutics International Inc. (OTCQB: IPCIF and TSX: IPCI) ("Intellipharmaceutics" or the...

Oncolytics Biotech (R) Announces a Publication Highlighting Synergistic Effect of Pelareorep with a Proteasome Inhibitor in Preclinical Models of Multiple Myeloma

- Combination Synergistic Even in Cells That Have Developed Resistance to Bortezomib - Article Published in the March 12 Edition...

Aytu BioScience Provides Study Update for Spermatogenesis Study of Natesto (R), the Only FDA-Approved, Nasally-Administered Testosterone Treatment

Interim Results Demonstrated Preservation of Sperm Parameters After Six Months of Treatment with Nasally-Administered Natesto Testosterone Gel Natesto Spermatogenesis Study...

error: Content is protected !!